Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Maternity
  4. Back
  5. Common obstetric problems, intrapartum labour ward
  6. Fetal Blood Sampling in Labour (627)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Fetal Blood Sampling in Labour (627)

Warning
Please report any inaccuracies or issues with this guideline using our online form

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. 

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty. 

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Definition

Fetal blood sample (FBS) refers to obtaining a sample of blood from the presenting part of the baby in utero, during labour.  It is used to measure fetal pH or lactate as a way of identifying hypoxaemia and acidosis and stratifying those who require urgent delivery.  

Acidosis reflects fetal hypoxaemia as when hypoxic, fetal metabolism changes from aerobic to anaerobic which results in the production of lactic acid.  This leads to a subsequent drop in fetal pH and provides a measure of the degree of hypoxaemia for the baby in labour.

Indications

The indications for FBS include:

  • pathological CTG in labour (cervix dilated >3 cm, membranes ruptured)

Pre-requisites

Before you start an FBS procedure, you must:

  • Start conservative measures and offer digital fetal scalp stimulation. Only continue with fetal blood sampling if the CTG trace remains pathological.

  • Confirm the position and dilatation of the cervix (>3 cm), station of the presenting part and ensure membranes are ruptured.

  • Explain the procedure to the woman and obtain her verbal consent (see below).

  • Ensure that the instruments are to hand and that the blood gas analyser is functioning.

  • Ensure there are no contraindications for the procedure.

Contraindications

The contraindications include:

  • An acute event, for example, cord prolapse, suspected placental abruption or suspected uterine rupture.
  • Acute fetal compromise as suggested by a prolonged ongoing fetal bradycardia of >3 minutes.

  • Risk of maternal- fetal infection transfer, for example maternal HIV, maternal hepatitis viruses or active herpes simplex virus.

  • Fetal bleeding disorders or suspected fetal bleeding disorders, for example haemophilia, maternal thrombocytopenia.

  • Prematurity, less than 34 weeks gestation (i.e. <34+0 weeks).

  • Face presentation.

  • The whole clinical picture indicates that the birth should be expedited, for example maternal sepsis, unstable pre-eclampsia.

  • Do not take a sample immediately following a prolonged deceleration.

Cautions

Be aware that for women with sepsis or significant meconium, fetal blood sampling results may be falsely reassuring. 

Obtaining consent

NICE guidelines 2017 recommend that when considering fetal blood sampling, explain the following to the woman and her birth companion(s):

  • Why the test is being considered and other options available, including the risks, benefits and limitations of each.
  • The blood sample will be used to measure the level of acid in the baby's blood, which may help to show how well the baby is coping with labour.

  • The procedure will require her to have a vaginal examination using a device similar to a speculum.

  • A sample of blood will be taken from the baby's head by making a small scratch on the baby's scalp. This will heal quickly after birth, but there is a small risk of infection.

  • What the different outcomes of the test may be (normal, borderline and abnormal) and the actions that will follow each result.

  • If a FBS cannot be obtained but there are fetal heart rate accelerations in response to the procedure, this is encouraging and in these circumstances expediting the birth may not be necessary.

  • If a FBS cannot be obtained and the cardiotocograph trace has not improved, expediting the birth will be advised.

  • A caesarean section or instrumental birth (forceps or ventouse) may be advised, depending on the results of the procedure.

Equipment

The sterile FBS pack contains as standard the following:

Sponge holder,  Amnioscope with attachable light source, 2 blades with blade holder, 5 capillary tubes and capillary tube holder, petroleum jelly, 6 large cotton swabs and 5 square green swabs.

In addition you will need

  • Lubricant gel –do not use Hibitane as this may alter the pH results
  • Ethyl chloride spray
  • Water for washing
  • Sterile gloves
  • Apron

Procedure

  • Ensure Labour Ward co-ordinator is aware you are undertaking this test prior to starting and ensure the blood gas analyser is ready to be used.

  • Place the woman either in a lithotomy or left lateral position with her right leg supported and abducted. Then drape the area around the perineum to provide a clean field.

  • Introduce the lubricated amnioscope. Direct the amnioscope posteriorly and sweep it anteriorly to catch the anterior lip of the cervix.

  • Remove the amnioscope’s obturator. Ideally, the cervix should not be visible. Try to visualise the fetal scalp clearly.

  • Clean the fetal scalp with a cotton wool swab, contamination with liquor or meconium can affect results. Spray the scalp with ethyl chloride to produce a reactive hyperaemia.

  • Apply a thin film of petroleum jelly with one of the large cotton wool swabs to increase surface tension on the fetal scalp; this encourages the formation of droplets of blood.

  • Insert the blade provided in the pack into the scalp to the full depth of the guard. Do not stroke the blade across the scalp as this may produce a lesion that is too large.

  • Collect the blood droplet into your capillary tube. At least two samples should be obtained. The second may be taken while the first is being analysed by an assistant.

  • Apply pressure to the fetal scalp with cotton wool swab at the end of the procedure if any bleeding is evident.

  • Reposition the mother comfortably and explain the results to her with your action plan.

Interpretation of results

A flow diagram for the interpretation of both pH and lactate is included at the end of this document.

pH rather than lactate is currently used within GGC for interpretation of fetal blood sampling, but please make sure you adhere to your local hospital policy.

The results should be interpreted taking into account the previous pH or lactate measurement, the rate of progress in labour and the clinical features of the woman and baby.

Where a FBS is indicated but a sample cannot be obtained and there is no improvement in the cardiotocograph trace, advise the woman that the birth should be expedited.

When planning to repeat an FBS, the time taken to obtain a sample must be taken into account

Post Delivery

If FBS is undertaken during labour, ensure paired cord gases are obtained at delivery and documented in the notes.

Fetal blood sampling flowchart

Editorial Information

Last reviewed: 19/04/2018

Next review date: 31/12/2022

Author(s): Julie Murphy.

Approved By: Obstetrics Clinical Governance Group

Document Id: 627

References

StratOG eLearning module, Fetal Blood Sampling, 2015, https://stratog.rcog.org.uk/tutorial/obstetrics/fetal-blood-sampling-5811

Intrapartum Care for healthy women and their babies, Clinical guideline [CG190], December 2014, updated  February 2017, https://www.nice.org.uk/guidance/cg190/chapter/Recommendations#monitoring-during-labour

RCOG Scientific Impact Paper No. 47, Is it time for UK obstetricians to accept Fetal Scalp lactate as an alternative to Fetal Scalp pH?  January 2015 https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip_47.pdf